Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Cardiff Oncology (CRDF) Depreciation and Depletion (2024 - 2025)

Cardiff Oncology (CRDF) has disclosed Depreciation and Depletion for 2 consecutive years, with $124000.0 as the latest value for Q4 2025.

Quarterly Depreciation and Depletion rose 34.78% to $124000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $399000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $400000.0 for FY2025, 0.0% changed from the prior year.
Depreciation and Depletion hit $124000.0 in Q4 2025 for Cardiff Oncology, up from $89000.0 in the prior quarter.
In the past five years, Depreciation and Depletion ranged from a high of $124000.0 in Q4 2025 to a low of $89000.0 in Q3 2025.